Next Article in Journal / Special Issue
Voltage-Gated Calcium Channel Antagonists and Traumatic Brain Injury
Previous Article in Journal
How “Pharmacoresistant” is Cav2.3, the Major Component of Voltage-Gated R-type Ca2+ Channels?
Previous Article in Special Issue
Calcium Channel Blockers as Tocolytics: Principles of Their Actions, Adverse Effects and Therapeutic Combinations
Pharmaceuticals 2013, 6(6), 777-787; doi:10.3390/ph6060777

Notes on Article Versions

NoteDate
Article Published29 May 2013 15:38 CEST
article pdf uploaded.29 May 2013 15:39 CEST
article word file uploaded.29 May 2013 15:39 CEST
article files uploaded.29 May 2013 15:39 CEST
article files uploaded.29 May 2013 15:39 CEST
article files uploaded.29 May 2013 15:39 CEST
article xml file uploaded13 September 2013 17:19 CEST
article html file updated13 September 2013 17:19 CEST
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert